Other languages MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
39.75 ^USD	-2.72%		-2.86%	-34.18%

05-07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT
05-07	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MoonLake Immunotherapeutics Q1 Net Loss Widens	05-07
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	04-10
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	03-10
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	03-04
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing	03-01
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing	03-01
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	02-29
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29
MoonLake Gains FDA, EMA Backing For Late-Stage Hidradenitis Suppurativa Trial	02-26
Moonlake Immunotherapeutics Insider Sold Shares Worth $1,208,418, According to a Recent SEC Filing	02-23
Moonlake Immunotherapeutics Insider Sold Shares Worth $5,917,368, According to a Recent SEC Filing	12-21
MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
MoonLake Immunotherapeutics Says Phase 2 Trial of Nanobody Sonelokimab Met Primary Endpoint	11-06
MoonLake Immunotherapeutics Announces Landmark Phase 2 Results for Nanobody Sonelokimab in Active Psoriatic Arthritis	11-05
MoonLake Immunotherapeutics Says Maintenance of Nanobody Sonelokimab Leads to Further Improvements	23-10-16
MoonLake Immunotherapeutics Announces the Full Dat Datasets from its 24-Week MIRA Clinical Trial, Establishing the Nanobody(R) Sonelokimab as Highly Promanded Therapeutics for Hidradenitis Suppurativa	23-10-15
Moonlake Immunotherapeutics Insider Bought Shares Worth $3,524,297, According to a Recent SEC Filing	23-10-10
MoonLake Immunotherapeutics Shares Rise After 10% Owner Disclosed Share Purchase	23-10-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Other languages

Filters